Nuvation Bio Inc
NUVB_t0.228USD
0.0000.00%
Handelsschluss 08/01, 16:00（ET）Kurse um 15 Minuten verzögert
0.00Marktkapitalisierung
--KGV TTM
mehr Informationen über Nuvation Bio Inc Unternehmen
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Unternehmensinformationen
BörsenkürzelNUVB_t
Name des UnternehmensNuvation Bio Inc
IPO-datumJul 01, 2020
CEODr. David T. Hung, M.D.
Anzahl der mitarbeiter- -
Wertpapierart- -
Geschäftsjahresende- -
Addresse357 Tehama Street, Floor 3
StadtSAN FRANCISCO
Börse- -
LandUnited States of America
Postleitzahl94103
Telefon14157543517
Websitehttps://www.nuvationbio.com/
BörsenkürzelNUVB_t
IPO-datumJul 01, 2020
CEODr. David T. Hung, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. Joe Rayne
Mr. Joe Rayne
Investor Relations
Investor Relations
--
--
Mr. Philippe Sauvage
Mr. Philippe Sauvage
Chief Financial Officer and Principal Financial Officer
Chief Financial Officer and Principal Financial Officer
--
--
Ms. Stacy Markel
Ms. Stacy Markel
Chief People Officer
Chief People Officer
--
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Gary Hattersley, Ph.D.
Dr. Gary Hattersley, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
--
--
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
--
--
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
--
--
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. Joe Rayne
Mr. Joe Rayne
Investor Relations
Investor Relations
--
--
Mr. Philippe Sauvage
Mr. Philippe Sauvage
Chief Financial Officer and Principal Financial Officer
Chief Financial Officer and Principal Financial Officer
--
--
Ms. Stacy Markel
Ms. Stacy Markel
Chief People Officer
Chief People Officer
--
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Gary Hattersley, Ph.D.
Dr. Gary Hattersley, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, Feb 28
Aktualisiert: Fri, Feb 28
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Other
100.00%
Aktionäre
Aktionäre
Anteil
Other
100.00%
Aktionärstypen
Aktionäre
Anteil
Other
100.00%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
30
31.74M
0.00%
+26.49M
2025Q1
30
31.74M
0.00%
+26.49M
2024Q4
31
4.90M
0.00%
-302.14K
2024Q3
30
4.86M
0.00%
-182.30K
2024Q2
31
4.71M
0.00%
+261.45K
2024Q1
29
4.01M
0.00%
-276.84K
2023Q4
27
4.00M
0.00%
-301.37K
2023Q3
26
4.18M
0.00%
-276.64K
2023Q2
26
4.34M
0.00%
-268.70K
2023Q1
26
4.49M
0.00%
-128.42K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Rock Springs Capital Management LP
134.03K
0%
--
--
Mar 31, 2025
Samsara BioCapital, LLC
133.33K
0%
--
--
Mar 31, 2025
Greenlight Capital, Inc.
100.00K
0%
--
--
Mar 31, 2025
Acuta Capital Partners, LLC
90.83K
0%
--
--
Mar 31, 2025
Citadel Advisors LLC
73.55K
0%
-408.00
-0.55%
Mar 31, 2025
Logos Global Management LP
66.67K
0%
--
--
Mar 31, 2025
Victory Capital Management Inc.
58.11K
0%
-440.00
-0.75%
Mar 31, 2025
Intellectus Partners, LLC
22.40K
0%
--
--
Mar 31, 2025
Boxer Capital Management, LLC
266.67K
0%
--
--
Mar 31, 2025
EcoR1 Capital, LLC
963.33K
0%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
